1. Home
  2. WNEB vs MOLN Comparison

WNEB vs MOLN Comparison

Compare WNEB & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western New England Bancorp Inc.

WNEB

Western New England Bancorp Inc.

HOLD

Current Price

$13.31

Market Cap

259.2M

Sector

Finance

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

N/A

Current Price

$4.18

Market Cap

157.8M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
WNEB
MOLN
Founded
1853
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Savings Institutions
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
259.2M
157.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
WNEB
MOLN
Price
$13.31
$4.18
Analyst Decision
Buy
Hold
Analyst Count
2
1
Target Price
$11.00
$3.75
AVG Volume (30 Days)
48.8K
2.3K
Earning Date
01-27-2026
10-30-2025
Dividend Yield
2.13%
N/A
EPS Growth
27.15
N/A
EPS
0.66
N/A
Revenue
$79,080,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.48
$1,000.00
P/E Ratio
$20.01
N/A
Revenue Growth
9.08
N/A
52 Week Low
$7.63
$3.36
52 Week High
$13.45
$5.91

Technical Indicators

Market Signals
Indicator
WNEB
MOLN
Relative Strength Index (RSI) 77.18 49.56
Support Level $12.62 $3.92
Resistance Level $13.45 $4.35
Average True Range (ATR) 0.33 0.17
MACD 0.07 -0.03
Stochastic Oscillator 71.04 37.68

Price Performance

Historical Comparison
WNEB
MOLN

About WNEB Western New England Bancorp Inc.

Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: